CI

At a glance

ClinicalIndex Comparison Record
Phase 1Recruiting· 345 target
Drug / intervention
NX-1607 +1 moredrug
Likely dose
Not stated in record
Key inclusion· 10
  • ✓Age 18 years or older
  • ✓Measurable disease per disease-specific response criteria
  • ✓Metastatic or unresectable disease; previously treated, not candidate for, or unable to receive standard treatment
  • ✓ECOG performance status 0 or 1
Key exclusion· 20
  • ✕Active untreated brain metastases
  • ✕Uncontrolled intercurrent illness including poorly controlled hypertension or diabetes, or ongoing active infection requiring systemic therapy
  • ✕Primary refractory EOC (no response to first platinum regimen or relapse <6 months after completion)
  • ✕Psychiatric illness limiting compliance with study requirements

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05107674
NCT05107674Phase 1RecruitingHigh MomentumUpdated 9mo ago
Long Recruiting
CompareCT.gov

A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage Lymphoma Proto-oncogene (CBL-B) Inhibitor, in Adults With Advanced Malignancies, With Phase 1b Expansion in Select Tumor Types

Nurix Therapeutics, Inc.·interventional·Posted Nov 4, 2021·Updated Sep 9, 2025

In Brief

A Phase 1 clinical trial evaluating NX-1607 and Paclitaxel for Ovarian Cancer, Epithelial and 13 related conditions. Currently recruiting, targeting 345 participants across 17 sites in 2 countries.

Signals

Enrolling ahead of pace

Detailed Summary

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic or Unresectable Melanoma, Non-small Cell Lung Cancer (NSCLC), Metastatic Castration-resistant Prostate Cancer (mCRPC), Malignant Pleural Mesothelioma (MPM), Triple Negative Breast Cancer (TNBC), Metastatic Urothelial Carcinoma, Cervical Cancer, Diffuse Large B Cell Lymphoma (DLBCL), Richter Transformation, Microsatellite Stable Colorectal Carcinoma
CountriesUnited Kingdom, United States
Collaborators--

Timeline

Phase 1Recruiting
2022202320242025202620272028
First PostedNov 4, 2021
Enrollment StartSep 29, 2021
Primary CompletionAug 31, 2026
Study CompletionFeb 28, 2028
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 4.7 years agoPrimary completion in 2 months

Interventions

NX-1607drug

Oral NX-1607

Paclitaxeldrug

Paclitaxel IV